0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover306.58%IV-57.14%PremiumDec 20, 2024Expiry Date10.00Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9401Delta0.0096Gamma1.67Leverage Ratio-0.0385Theta0.0032Rho1.57Eff Leverage0.0048Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet